Exhibit 107
Calculation of Filing Fee Table
Form F-3
(Form Type)
NLS Pharmaceutics Ltd.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered(1) | Proposed Maximum Offering Price Per Share(2)(3) | Maximum Aggregate Offering Price(1) | Fee Rate | Amount of Registration Fee | |||||||||||||||||
| Equity | Common Shares, par value CHF 0.02 | 457(c) | 806,452 | $ | 4.975 | $ | 4,012,099 | $ | 0.00015310 | $ | 614.2524 | |||||||||||||
| Equity | Preferred shares convertible into Common shares | 457(c) | – | – | – | – | ||||||||||||||||||
| Equity | Common share underlying preferred shares | 457(c) | 806,452 | $ | 4.975 | $ | 4,012,099 | $ | 0.00015310 | 614.2524 | ||||||||||||||
| Equity | Common warrants to purchase common shares | 457(c) | – | – | - | – | ||||||||||||||||||
| Equity | Pre-funded warrants to purchase common shares | 457(c) | – | – | ||||||||||||||||||||
| Equity | Common shares underlying the common warrants and pre-funded warrants | 457(c) | 1,134,533 | $ | 4.975 | $ | 5,644,302 | $ | 0.00015310 | $ | 864.1426 | |||||||||||||
| Total Offering Amounts | $ | 13,668,500 | $ | 2,092.65 | ||||||||||||||||||||
| Total Fees Previously Paid | $ | - | ||||||||||||||||||||||
| Total Fee Offsets | $ | – | ||||||||||||||||||||||
| Net Fee Due | $ | 2,092.65 | ||||||||||||||||||||||
| (1) | Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the Common Shares, par value CHF 0.02 per share, or Common Shares, being registered, Common Shares issuable upon conversion of the preferred shares and the Common Shares that are issuable upon the exercise of the common warrants and pre-funded warrants, that are registered hereby also include an indeterminate number of additional Common Shares as may from time to time become issuable by reason of share splits, stock dividends, recapitalizations or other similar transactions. |
| (2) | Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low sales prices of the Common Shares on the Nasdaq Capital Market on October 21, 2024. |
| (3) | The Registrant will not receive any proceeds from the sale of its Common Shares by the selling shareholders. |
| (4) | All Common Shares are to be offered for resale by the selling shareholders named in the prospectus contained in this Registration Statement on Form F-3. |
